These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 29757257)

  • 1. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
    Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
    Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
    Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
    Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
    Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
    Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
    Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
    Talos DM; Jacobs LM; Gourmaud S; Coto CA; Sun H; Lim KC; Lucas TH; Davis KA; Martinez-Lage M; Jensen FE
    Ann Neurol; 2018 Feb; 83(2):311-327. PubMed ID: 29331082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR Regulation of N-Myc Downstream Regulated 1 (NDRG1) Phosphorylation in Clear Cell Renal Cell Carcinoma.
    Valluri A; Wellman J; McCallister CL; Brown KC; Lawrence L; Russell R; Jensen J; Denvir J; Valentovic MA; Denning KL; Salisbury TB
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants.
    Liu J; Brown RE
    Mod Pathol; 2011 Dec; 24(12):1553-9. PubMed ID: 21822208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTOR downregulates iodide uptake in thyrocytes.
    de Souza EC; Padrón AS; Braga WM; de Andrade BM; Vaisman M; Nasciutti LE; Ferreira AC; de Carvalho DP
    J Endocrinol; 2010 Jul; 206(1):113-20. PubMed ID: 20392814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.